NR4A2 and neurodegenerative disease: Observations of diminished Nurr1 levels in patients7 and animal models8–10 of Alzheimer’s (AD) and Parkinson’s diseases (PD) underline the therapeutic potential of Nurr1 activation in neurodegenerative diseases.